Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
927 Results for "
Lymphomas
" in MedChemExpress (MCE) Product Catalog:
Products (927)
927 Results for "Lymphomas" in MCE Product Catalog:
Cat. No.: HY-170434
CAS No.: 3106363-91-8
Target:
Research Areas:
Bfl-1-IN-6 is an orally active BFL1 inhibitor with an IC50 of 19 nM. Bfl-1-IN-6 selectively binds covalently to BFL1, stabilizes the protein and displaces BIM from BFL1, thereby inducing apoptosis activity. Bfl-1-IN-6 stabilizes BFL1 protein, activates cleaved caspase 3, and exhibits antitumor activity in mouse models. Bfl-1-IN-6 can be used for the research of hematological malignancies .
Cat. No.: HY-170434A
CAS No.: 3106364-91-1
Target:
Research Areas:
Bfl-1-IN-6 TFA is an orally active BFL1 inhibitor with an IC50 of 19 nM. Bfl-1-IN-6 TFA selectively binds covalently to BFL1, stabilizes the protein and displaces BIM from BFL1, thereby inducing apoptosis activity. Bfl-1-IN-6 TFA stabilizes BFL1 protein, activates cleaved caspase 3, and exhibits antitumor activity in mouse models. Bfl-1-IN-6 TFA can be used for the research of hematological malignancies .
Target:
Research Areas:
Glutarimide is a CRBN binder. Glutarimide exerts its function by binding to the thalidomide-binding domain of the CRBN protein. Glutarimide serves as an important structural component of many biologically active compounds. Glutarimide can be used in studies related to anemia, multiple myeloma and cycloheximide .
Cat. No.: HY-P99641
CAS No.: 1808081-43-7
Target:
Research Areas:
Cat. No.: HY-111556R
CAS No.: 2361493-16-3
Target:
Research Areas:
BSJ-03-123 (Standard) is the analytical standard of BSJ-03-123 (HY-111556). This product is intended for research and analytical applications. BSJ-03-123 is a selective PROTAC degrader of CDK6. BSJ-03-123 degrades CDK6, thereby inhibiting Rb S780 phosphorylation and inducing G1 phase arrest, while remodeling cell cycle and transcriptional signaling, with no effect on CDK4-dependent cancer cells. BSJ-03-123 reduces CDK6 protein levels in mouse ovarian tissues, increases the proportion of primordial follicles, and induces granulosa cell apoptosis, without impairing the ability of oocytes to resume meiosis and mature to the MII stage. BSJ-03-123 alleviates uveitis by blocking the HDACs-CDK6/ID2 axis. BSJ-03-123 can be used in studies related to acute myeloid leukemia, mantle cell lymphoma and autoimmune uveitis .
Cat. No.: HY-L079
4,333 compounds
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
Research Areas:
Infection Neurological Disease Inflammation/Immunology Cancer
Eicosatetraynoic acid (ETYA) is a non-metabolizable analog of Arachidonic acid (HY-109590) and also an inhibitor of the lipoxygenase (LOX)/cyclooxygenase (COX) pathway (ID50 = 8 μM and 4 μM). Eicosatetraynoic acid acts as a suicide substrate to inhibit the production of inflammatory mediators such as leukotrienes and prostaglandins. Eicosatetraynoic acid acts directly on cell membranes and membrane proteins to exert a wide range of effects, including blocking potassium channels, increasing cell membrane fluidity, elevating intracellular calcium levels, inhibiting DNA synthesis in tumor cells, inducing differentiation of certain cells, and specifically inhibiting the assembly and replication of orthopoxviruses. Eicosatetraynoic acid alleviates acute lung injury induced by chemicals such as phosgene .
Cat. No.: HY-184193
Target:
Research Areas:
M9101 is a selective Aurora A PROTAC degrader with a DC50 of 2.3 nM. M9101 induces G2/M arrest in triple-negative breast cancer cells and potently inhibits the proliferation of multiple tumor cell lines. M9101 can be used in the research of various cancers including triple-negative breast cancer .
Cat. No.: HY-N19666
CAS No.: 1820968-26-0
Category:
Target:
Cat. No.: HY-P99215
CAS No.: 1312797-14-0
Synonyms: Anti-EGFL7; RG 7414
Cat. No.: HY-129108
CAS No.: 205252-57-9
Synonyms: (9Z)-UAB-30
Research Areas:
9-cis-UAB30 is a rexinoid agonist. 9-cis-UAB30 significantly decreases the proliferation, viability, and motility of both patient-derived xenografts (PDXs). 9-cis-UAB30 induced cell-cycle arrest as demonstrated by the significant increase in the percentage of cells in G1 and a decrease in the percentage of cells in S phase by downregulating SKP2 and/or 20S proteasome activity, which leads to increased p27kip1 protein stability. 9-cis-UAB30 downregulates the abundance of stem cell marker mRNAs (Oct4, Nanog, Sox2, nestin) and upregulates the abundance of differentiation marker mRNAs (β3-tubulin, NSE, HOXC9, GAP43). 9-cis-UAB30 has no adverse effects on the central nervous system and cardiovascular system at the tested dose. 9-cis-UAB30 can be used for the study of neuroblastoma, cutaneous T-cell lymphomas, and breast cancer .
Target:
Research Areas:
Leyk is an orally active Cysteine derivative. Leyk stimulates bone marrow hematopoiesis. Leyk exerts a significant protective effect against cyclophosphamide-induced leukopenia. Leyk can be used in studies related to thrombocytopenia and leukopenia .
Category:
Infection Alkaloids Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Disease Research Fields Cancer Indole Alkaloids
Target:
Cat. No.: HY-P4122
CAS No.: 1676104-81-6
Cat. No.: HY-P992439
Cat. No.: HY-W017180
CAS No.: 72707-66-5
Synonyms: α-(Bromomethyl)acrylic acid; α-Methylated acrylamide; α-MAA
Target:
Research Areas:
2-(Bromomethyl) acrylic acid (α-MAA) is a component of Ibt-DOX (HY-181546) .
Cat. No.: HY-N7695
CAS No.: 23133-56-4
Cat. No.: HY-10446A
CAS No.: 1320211-69-5
Target:
Research Areas:
(S)-Pralatrexate is an orally active anticancer compound. (S)-Pralatrexate exhibits cytotoxic activity against cancer cells and possesses anti-inflammatory activity. (S)-Pralatrexate can be used in research related to prostate cancer, breast cancer, rheumatoid arthritis, etc.
Synonyms: Brigatinib analog
Target:
Research Areas:
ALK-IN-1 is an orally active, blood-brain barrier-permeable ALK and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
